Opus Genetics (NASDAQ:IRD) Issues Quarterly Earnings Results

Opus Genetics (NASDAQ:IRD) announced its quarterly earnings results on Monday. The company reported ($1.27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.93), Zacks reports. The firm had revenue of $3.40 million during the quarter, compared to the consensus estimate of $11.10 million. Opus Genetics had a negative return on equity of 63.65% and a negative net margin of 324.45%.

Opus Genetics Trading Down 2.3 %

IRD traded down $0.02 during trading on Monday, reaching $0.99. The company had a trading volume of 75,647 shares, compared to its average volume of 218,777. The business’s 50 day moving average is $1.08. The company has a market capitalization of $31.63 million, a PE ratio of -0.91 and a beta of 0.28. Opus Genetics has a 52 week low of $0.81 and a 52 week high of $1.56.

Analyst Ratings Changes

Separately, HC Wainwright reissued a “buy” rating and issued a $8.00 price objective on shares of Opus Genetics in a report on Wednesday, February 19th.

About Opus Genetics

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc, formerly known as Ocuphire Pharma Inc, is based in Farmington Hills, Michigan.